Skip to main contentAI and Advanced
/
ASTRAZEN · NSEBSE SENSEX77,537.72+0.82%BSE |
NIFTY 5024,231.85+0.64%NSE |
NIFTY BANK57,495.9+0.45%NSE |
NIFTY IT30,673.05+0.79%NSE |
NIFTY AUTO29,301.75+0.40%NSE |
NIFTY FMCG47,863.25+0.82%NSE |
NIFTY PHARMA26,416+0.39%NSE |
NIFTY 50023,512.95+0.54%NSE |
AS
NSE · Equity shares · Biotechnology & Drugs0.00 · 0.00%
AstraZeneca Pharma India Ltd ASTRAZEN
NSE:INR 7,500
BSE:INR 8,074
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections8 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for ASTRAZEN
Analysis, reports, chat and Advanced access use the same ShareKeyX account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 7,500
Day rangeINR 7,485 — INR 7,620
52-week rangeINR 7,481 — INR 9,849.5
Volume9,210
Market cap20,400.82
P/ENot available
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)2,275.58
Net Income (INR Cr)187.52
EPS76.61
Research path: Interpret AstraZeneca Pharma India Ltd's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
ASTRAZENAstraZeneca Pharma India Ltd1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 1,989.1 | 1,518.12 | 1,078.03 |
| Accumulated Depreciation Total | -67.29 | -151.79 | -120.32 |
| Cash Equivalents | 425.76 | 509.33 | 486.7 |
| Other Liabilities Total | 37.75 | 15.32 | 6.21 |
| Accrued Expenses | 58.79 | 101.96 | 55.23 |
| Common Stock Total | 5 | 5 | 5 |
| Other Current Assets Total | 1.75 | 2 | 2.11 |
| Prepaid Expenses | 11.2 | 14.21 | 10.96 |
| Total Assets | 1,989.1 | 1,518.12 | 1,078.03 |
| Current Portof LT Debt/Capital Leases | 13.91 | 6.28 | 1.81 |
| Cash | 21.96 | 26.81 | 18.87 |
| Total Equity | 872.79 | 770.35 | 711.92 |
| Long Term Investments | 3.67 | 3.4 | Not available |
| Retained Earnings(Accumulated Deficit) | 861.28 | 758.2 | 703.63 |
| Total Common Shares Outstanding | 2.5 | 2.5 | 2.5 |
| Property/Plant/Equipment Total-Gross | 184.76 | 215.37 | 185.16 |
| Tangible Book Valueper Share Common Eq | 349.12 | 307.88 | 283.92 |
| Total Liabilities | 1,116.31 | 747.77 | 366.11 |
| Total Debt | 110.66 | 35.73 | 4.59 |
| Cashand Short Term Investments | 447.72 | 536.14 | 505.57 |
| Total Receivables Net | 242.18 | 239.83 | 185.4 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 |
| Accounts Receivable-Trade Net | 214.7 | 186.87 | 155.4 |
| Property/Plant/Equipment Total-Net | 117.47 | 63.58 | 64.84 |
| Total Current Liabilities | 981.81 | 703 | 357.12 |
| Total Inventory | 1,029.34 | 550.17 | 228.67 |
| ESOP Debt Guarantee | 6.51 | 7.15 | 3.29 |
| Accounts Payable | 782.7 | 456.3 | 196.51 |
| Other Currentliabilities Total | 126.41 | 138.46 | 103.57 |
| Total Long Term Debt | 96.75 | 29.45 | 2.78 |
| Intangibles Net | 0 | 0.66 | 2.11 |
| Other Long Term Assets Total | 55.28 | 46.19 | 23.72 |
| Note Receivable-Long Term | 80.49 | 61.94 | 54.65 |
| Total Current Assets | 1,732.19 | 1,342.35 | 932.71 |
| Capital Lease Obligations | 96.75 | 29.45 | 2.78 |
Fundamentals
Valuation and ratios
Valuation
Price to Sale Ratio8.97
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskModerate risk
Board Risk24.41
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
Peer data unavailable in the company profile payload.
Shareholding
Ownership
- Promoter
- 75.00%
- FII
- 2.68%
- MF
- 6.01%
- Other
- 16.31%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
AstraZeneca Pharma India Limited Announces Resignation of Bhavana Agrawal from Executive Director, Effective August 31, 2026 - marketscreener.comMarket news · 21 Jul 2026, 5:38 pm
AstraZeneca Pharma India Limited Announces Resignation of Bhavana Agrawal from Executive Director, Effective August 31, 2026 marketscreener.com
AstraZeneca Pharma CFO Bhavana Agrawal Resigns Effective August 31, 2026, For Group Role - SahiMarket news · 21 Jul 2026, 10:43 am
AstraZeneca Pharma CFO Bhavana Agrawal Resigns Effective August 31, 2026, For Group Role Sahi
AstraZeneca Pharma India files BRSR for FY26 - scanx.tradeMarket news · 18 Jul 2026, 11:37 pm
AstraZeneca Pharma India files BRSR for FY26 scanx.trade
Astrazeneca Pharma India Limited Proposes Dividend for Financial Year 2025-26 - marketscreener.comMarket news · 18 Jul 2026, 11:35 pm
Astrazeneca Pharma India Limited Proposes Dividend for Financial Year 2025-26 marketscreener.com
Price to book forward of AstraZeneca Pharma India Limited – NSE:ASTRAZEN - TradingViewMarket news · 18 Jul 2026, 9:21 pm
Price to book forward of AstraZeneca Pharma India Limited – NSE:ASTRAZEN TradingView
AstraZeneca fixes July 31 record date for ₹36 dividend - scanx.tradeMarket news · 18 Jul 2026, 7:14 pm
AstraZeneca fixes July 31 record date for ₹36 dividend scanx.trade
Corporate actions
Events
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.36.0000 per share(1800%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- annual General MeetingPOM
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
ShareKeyX Community
Discussion and sentiment for AstraZeneca Pharma India Ltd
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and ShareKeyX AI.
Checking your ShareKeyX account…
Company profile
Business information
What the company does
Not available
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- ASTRAZEN
- BSE Code
- 506820
Questions
Stock FAQ
What is the symbol and ISIN of AstraZeneca Pharma India Ltd?
AstraZeneca Pharma India Ltd has the symbol ASTRAZEN and ISIN - INE203A01020.
What is the current price of AstraZeneca Pharma India Ltd?
AstraZeneca Pharma India Ltd is currently trading at INR 7,500.00.
What are the year high and year low of AstraZeneca Pharma India Ltd?
AstraZeneca Pharma India Ltd has a year high of INR 9,849.50 and a year low of INR 7,481.00.
What is the market capitalization of AstraZeneca Pharma India Ltd?
AstraZeneca Pharma India Ltd has a market capitalization of INR 20,400.82 crore.
What is the P/E ratio of AstraZeneca Pharma India Ltd?
AstraZeneca Pharma India Ltd has a P/E ratio of NA.
What is the dividend yield of AstraZeneca Pharma India Ltd?
AstraZeneca Pharma India Ltd has a dividend yield of NA.
How is the financial performance of AstraZeneca Pharma India Ltd based on revenue, net income, and EPS?
AstraZeneca Pharma India Ltd has revenue of INR 2,275.58 crore, net income of INR 187.52 crore, and EPS of NA.
What is the book value of AstraZeneca Pharma India Ltd?
AstraZeneca Pharma India Ltd has a book value of NA.
What is the debt-to-equity ratio of AstraZeneca Pharma India Ltd?
AstraZeneca Pharma India Ltd has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of AstraZeneca Pharma India Ltd?
AstraZeneca Pharma India Ltd has a price-to-book ratio of NA and a price-to-sales ratio of 8.97.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.